R

ise and shine, everyone. The middle of the week is upon us. Have heart, though. You made it this far, so why not hang on for another couple of days, yes? After all, consider the alternatives. And what better way to make the time fly than to keep busy. So grab that cup of stimulation — our flavor today boasts the aroma of blueberries — and get started. Meanwhile, do keep us in mind if you hear anything interesting. We love secrets. Have a smashing day …

Food and Drug Administration Commissioner Scott Gottlieb, who is considered a potential successor to recently departed U.S. Health and Human Services Secretary Tom Price, tells Reuters that he can best serve the Trump administration in his current role. “I feel like I want to continue to follow through on the policies we’ve put out and it’s where I think I can be most effective,” he says.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Since you cannot ‘inspect quality in,’ don’t let inspectors become too familiar with your medical device plant. Rotate those who come – so there will be less chance of recalls. Yes, we wouldn’t want FDA personnel to be come expert in the processes of a site. “Good grief, Charley Brown!”

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy